^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Venetoclax + obinutuzumab
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Lymphocytic Leukemia)
New
Title:

venetoclax (Venclyxto®) is accepted for restricted use within NHSScotland.

Excerpt:
Venetoclax (Venclyxto®) is accepted for restricted use within NHSScotland....In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)....for use in (1) patients without del (17p)/TP53 mutation who are not fit to receive FCR (fludarabine, cyclophosphamide and rituximab) chemo-immunotherapy and (2) patients with del (17p)/TP53 mutation.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Excerpt:
...- TP53 mutation status (if completed) must be obtained within 12 months prior to registration...